Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
Loyola University Medical Center
mi
from
Maywood, IL
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
Illinois Oncology Research Association CCOP
mi
from
Peoria, IL
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
Illinois Oncology Research Association CCOP
mi
from
Peoria, IL
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
Memorial Medical Center
mi
from
Springfield, IL
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
Memorial Medical Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
Indiana University Medical Center
mi
from
Indianapolis, IN
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
Indiana University Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
University of Michigan University Hospital
mi
from
Ann Arbor, MI
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
University of Michigan University Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
University of Michigan
mi
from
Ann Arbor, MI
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
Saint John's Mercy Medical Center
mi
from
Saint Louis, MO
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
Saint John's Mercy Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
New York Cancer Consortium
mi
from
Bronx;, NY
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
New York Cancer Consortium
mi
from
Bronx;, NY
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
New York University Langone Medical Center
mi
from
New York, NY
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
New York University Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
Saint Luke's Roosevelt Hospital Center - Saint Luke's Division
mi
from
New York, NY
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
Saint Luke's Roosevelt Hospital Center - Saint Luke's Division
mi
from
New York, NY
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
Columbia University Medical Center
mi
from
New York, NY
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
Weill Medical College of Cornell University
mi
from
New York, NY
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated:  12/16/2015
Virginia Commonwealth University
mi
from
Richmond, VA
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Status: Enrolling
Updated: 12/16/2015
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor MSC2156119J Under Three Different Regimens in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/16/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor MSC2156119J Under Three Different Regimens in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/16/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Prospective Randomized Controlled Trial Comparing Water and Air Colonoscopy in a Community Based Setting
Prospective Randomized Controlled Trial Comparing Water Exchange Colonoscopy and Air Colonoscopy in a Community Based Setting
Status: Enrolling
Updated:  12/16/2015
Elk Grove PCN, University of California, Davis
mi
from
Elk Grove, CA
Prospective Randomized Controlled Trial Comparing Water and Air Colonoscopy in a Community Based Setting
Prospective Randomized Controlled Trial Comparing Water Exchange Colonoscopy and Air Colonoscopy in a Community Based Setting
Status: Enrolling
Updated: 12/16/2015
Elk Grove PCN, University of California, Davis
mi
from
Elk Grove, CA
Click here to add this to my saved trials
Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema
Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema in High Risk Patients
Status: Enrolling
Updated:  12/16/2015
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema
Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema in High Risk Patients
Status: Enrolling
Updated: 12/16/2015
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
A Phase II Study of OSI-774 in Combination With Bevacizumab in Patients With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/16/2015
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
A Phase II Study of OSI-774 in Combination With Bevacizumab in Patients With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/16/2015
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
A Phase II Study of OSI-774 in Combination With Bevacizumab in Patients With Stage IV Breast Cancer
Status: Enrolling
Updated:  12/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
A Phase II Study of OSI-774 in Combination With Bevacizumab in Patients With Stage IV Breast Cancer
Status: Enrolling
Updated: 12/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma
Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma
Status: Enrolling
Updated:  12/16/2015
Indiana University Cancer Center
mi
from
Indianapolis, IN
Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma
Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma
Status: Enrolling
Updated: 12/16/2015
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib
A Phase 2 Trial of Dasatinib in Patients With Lung Adenocarcinoma With Acquired Resistance to Erlotinib or Gefitinib
Status: Enrolling
Updated:  12/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib
A Phase 2 Trial of Dasatinib in Patients With Lung Adenocarcinoma With Acquired Resistance to Erlotinib or Gefitinib
Status: Enrolling
Updated: 12/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data
Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data
Status: Enrolling
Updated:  12/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data
Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data
Status: Enrolling
Updated: 12/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer
Pilot Study: Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated:  12/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer
Pilot Study: Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated: 12/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/16/2015
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/16/2015
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/16/2015
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/16/2015
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/16/2015
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/16/2015
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Click here to add this to my saved trials
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/16/2015
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/16/2015
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/16/2015
Memoral Sloan Kettering Cancer Center@Phelps
mi
from
Sleepy Hollow, NY
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/16/2015
Memoral Sloan Kettering Cancer Center@Phelps
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging
Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging
Status: Enrolling
Updated:  12/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging
Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging
Status: Enrolling
Updated: 12/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer
Effect of Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Clinical Outcome and Correlation to Biological Parameters
Status: Enrolling
Updated:  12/17/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer
Effect of Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Clinical Outcome and Correlation to Biological Parameters
Status: Enrolling
Updated: 12/17/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer
A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Boston, MA
Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer
A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer
A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Detroit, MI
Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer
A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer
A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Dallas, TX
Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer
A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer
A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease
Status: Enrolling
Updated:  12/17/2015
Research Site
mi
from
Barcelona,
Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer
A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease
Status: Enrolling
Updated: 12/17/2015
Research Site
mi
from
Barcelona,
Click here to add this to my saved trials
Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma
Evaluation of Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma
Status: Enrolling
Updated:  12/17/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma
Evaluation of Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma
Status: Enrolling
Updated: 12/17/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
PET Scans in Diagnosing Primary or Recurrent Cervical Cancer in Patients Who Are Undergoing Surgery
A Pilot Study of 18F-Flourodeoxyglucose Positron Emission Tomography in the Diagnosis of Primary and Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
PET Scans in Diagnosing Primary or Recurrent Cervical Cancer in Patients Who Are Undergoing Surgery
A Pilot Study of 18F-Flourodeoxyglucose Positron Emission Tomography in the Diagnosis of Primary and Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Huang Lian (Chinese Herb) in Treating Patients With Advanced Solid Tumors
A Phase I Study Of The Chinese Herb Huanglian (Coptis Chinesis) In Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Huang Lian (Chinese Herb) in Treating Patients With Advanced Solid Tumors
A Phase I Study Of The Chinese Herb Huanglian (Coptis Chinesis) In Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Massage Therapy in Treating Patients With Cancer Pain
Massage for the Treatment of Pain in Cancer: A Randomized Phase II Study
Status: Enrolling
Updated:  12/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Massage Therapy in Treating Patients With Cancer Pain
Massage for the Treatment of Pain in Cancer: A Randomized Phase II Study
Status: Enrolling
Updated: 12/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
Phase II Study of Sunitinib in Metastatic Transitional Cell Carcinoma of the Urothelium
Status: Enrolling
Updated:  12/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
Phase II Study of Sunitinib in Metastatic Transitional Cell Carcinoma of the Urothelium
Status: Enrolling
Updated: 12/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model
A Multicenter, Phase I/II Study of Every Other Week Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model
Status: Enrolling
Updated:  12/17/2015
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model
A Multicenter, Phase I/II Study of Every Other Week Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model
Status: Enrolling
Updated: 12/17/2015
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model
A Multicenter, Phase I/II Study of Every Other Week Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model
Status: Enrolling
Updated:  12/17/2015
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model
A Multicenter, Phase I/II Study of Every Other Week Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model
Status: Enrolling
Updated: 12/17/2015
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Click here to add this to my saved trials